ArticleScientific reports2025
Comprehensive analysis of malignant subtypes of lung adenocarcinoma based on multi-omics landscape and functional validation of prognostic biomarker BAIAP2L2.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung adenocarcinoma, the predominant pathogenic type of lung cancer, exhibits intricate biological behaviors and molecular pathways, which have consistently been a focal point and challenge in tumor research. The integration of multi-omics technologies and diverse analytical methodologies facilitates an in-depth study of lung adenocarcinoma's characteristics at cellular, molecular, and clinical dimensions, providing a theoretical foundation and prospective targets for precise diagnosis and effective treatment. scRNA-seq and RNA-seq data were obtained from public databases. The epithelial cells of lung adenocarcinoma were analyzed by methods such as CNV level assessment, cell trajectory analysis, malignant cell identification, and cell communication analysis, and the marker genes of malignant cells were extracted. In the RNA-seq data, CoxBoost was used for prognostic modeling to mine the risk gene BAIAP2L2 for further analysis. The effect of BAIAP2L2 on lung adenocarcinoma was verified by cell experiments. There is obvious heterogeneity among the epithelial cells of lung adenocarcinoma, and significant differences exist between different cell subgroups. The malignant differentiation of lung adenocarcinoma cells has a clear trajectory, and epithelial cell subgroups may influence the differentiation direction through cell communication. The CoxBoost model established based on the marker genes of malignant cells has a relatively good predictive effect, and BAIAP2L2 can serve as a prognostic factor for lung adenocarcinoma. In vitro cellular experiments demonstrated that interfering with BAIAP2L2 can impede the proliferation, migration, and invasion of lung adenocarcinoma cells, along with the epithelial-mesenchymal transition of these cells. BAIAP2L2 is a prognostic factor for lung adenocarcinoma, and interfering with BAIAP2L2 can inhibit the growth, metastasis, and epithelial-mesenchymal transition of lung adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.